Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

Inclusion Criteria: * Histologically confirmed\* solid tumor, including any of the following: * Ewing's sarcoma/peripheral primitive neuroectodermal tumor (PNET) * Osteosarcoma * Rhabdomyosarcoma * Neuroblastoma * High-grade astrocytoma * Low-grade astrocytoma * Glioblastoma multiforme * Ependymoma * Hepatoblastoma * Germ cell tumors of any site * Rare tumors of interest, including any of the following: * Soft tissue sarcoma * Hepatocellular carcinoma * Childhood/adolescent colorectal carcinoma * Childhood/adolescent renal cell carcinoma * Childhood/adolescent adrenocortical carcinoma * Childhood/adolescent nasopharyngeal carcinoma * Recurrent disease OR refractory to conventional therapy * Measurable disease by clinical exam, CT scan, MRI, or positron emission tomography * Performance status - Karnofsky 50-100% (for patients over age 10) * Performance status - Lansky 50-100% (for patients age 10 and under) * At least 8 weeks * Absolute neutrophil count ≥ 1,000/mm\^3\* * Platelet count ≥ 75,000/mm\^3\* (transfusion independent) * Hemoglobin ≥ 8.0 g/dL\* (RBC transfusions allowed) * Granulocytopenia, anemia, and/or thrombocytopenia due to bone marrow metastases or extensive prior radiotherapy allowed provided the above hematological criteria are met * Bilirubin ≤ 3 mg/dL * Creatinine based on age as follows: * ≤ .8 mg/dL (for patients age 5 and under) * ≤ 1.0 mg/dL (for patients age 6 to 10) * ≤ 1.2 mg/dL (for patients ag…